1616 Rhode Island Ave., NW
Washington, D.C., 20036
Ambassador William R. Brownfield, Assistant Secretary of State for International Narcotics and Law Enforcement Affairs, will lead off with remarks on U.S. and international drug policies, drawing from his participation in the recent meeting of the UN Commission on Narcotic Drugs (CND), held on March 13-14 in Vienna, Austria. As the premier drug control policy making body within the UN system, the CND addressed countering illicit drugs and the power of criminal cartels, strengthening public health approaches, and recent legal changes and the challenges of judicial coordination. The CND is also one of several bodies contributing to debates in the lead-up to the 2016 UN Special Session on Drugs. Following Ambassador Brownfield’s address, there will be a roundtable conversation, moderated by J. Stephen Morrison, Senior Vice President and Director of the CSIS Global Health Policy Center, that will feature Ambassador Brownfield, Kevin Sabet, former Senior Advisor to Director Kerlikowske at the White House Office of National Drug Control Policy and currently Director of the Drug Policy Institute at the University of Florida, Michel Kazaktchine and Ruth Dreifuss, two members of the Global Commission on Drug Policy launched in 2011 by 22 international leaders with a special focus on harm reduction and related public health approaches. Michel Kazatchkine is also the former Executive Director of the Global Fund to Fight AIDS, Tuberculosis, and Malaria and currently the UNSG’s Special Envoy on HIV/AIDS for Eastern Europe and Central Asia. Ruth Dreifuss is the former Minister of Health and President of the Swiss Confederation.
Post Disaster Mental Health in Japan: Lessons and challenges In this commentary we present three observations about the shortcomings of Japan's disaster response policies specifically with reference to post-disaster mental health services, and offers concrete recommendations for strengthening future responses.
A Strategic Approach to Malaria Significant cost savings may be elusive: experts caution against assuming it will be easy or simple to lower market prices for bed nets, spraying, and therapies. If anything, some future new technologies may add costs.